Antiepileptic Drugs for the Acute and Maintenance Treatment of Bipolar Disorder

REFERENCES

• Schou M, Juel-Neilsen N, Stro¨mgren E, Voldby H. The treat- ment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954;17:250–60.
   PubMed Web of Science ®Google Scholar
• Maggs R. Treatment of manic illness with lithium carbonate. Br J Psychiatry 1963;109:56–65.
   Web of Science ®Google Scholar
• Goodwin FK, Murphy DL, Bunney WE Jr. Lithium- carbonate treatment in depression and mania: a longitudinal double-blind study. Arch Gen Psychiatry 1969;21:486–96.
   PubMed Web of Science ®Google Scholar
• Stokes PE, Shamoian CA, Stoll PM, Patton MJ. Efficacy of lithium as acute treatment of manic-depressive illness. Lan- cet 1971;1:1319–25.
   PubMed Web of Science ®Google Scholar
• Spring G, Schweid D, Gray C, Steinberg J, Horwitz M. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states. Am J Psychiatry 1970;126:1306–10.
   PubMed Web of Science ®Google Scholar
• Johnson G, Gershon S, Burdock EI, Floyd A, Hekimian L. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br J Psychiatry 1971;119:267–76.
   PubMed Web of Science ®Google Scholar
• Prien RF, Caffey EM Jr, Klett CJ. Comparison of lithium car- bonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972;26:146–53.
   PubMed Web of Science ®Google Scholar
• Takahashi R, Sakuma A, Itoh K, Itoh H, Kurihara M. Com- parison of efficacy of lithium carbonate and chlorpromazine in mania: report of Collaborative Study Group on Treatment of Mania in Japan. Arch Gen Psychiatry 1975;32:1310–8.
   Google Scholar
• Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54:37–42.
   PubMed Web of Science ®Google Scholar
• Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974;30:229–33.
   PubMed Web of Science ®Google Scholar
• Maj M, Del Vecchio M, Starace F, Pirozzi R, Kemali D. Pre- diction of affective psychoses response to lithium prophy- laxis: the role of socio-demographic, clinical, psychological and biological variables. Acta Psychiatr Scand 1984;69:37–44.
   Google Scholar
• Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Wa- ternaux C. Episode sequence in bipolar disorder and re- sponse to lithium treatment. Am J Psychiatry 1991;148:1237–9.
   Google Scholar
• Kulhara P, Basu D, Mattoo SK, Sharan P, Chopra R. Lithium prophylaxis of recurrent bipolar affective disorder: long-term outcome and its psychosocial correlates. J Affect Disord 1999; 54:87–96.
   Google Scholar
• O’Connell RA, Mayo JA, Flatow L, Cuthbertson B, O’Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991;159:123–9.
   PubMed Web of Science ®Google Scholar
• Post RM, Putnam F, Contel NR, Goldman B. Electroconvul- sive seizures inhibit amygdala kindling: implications for mechanisms of action in affective illness. Epilepsia 1984; 25:234–9.
   PubMedGoogle Scholar
• Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969;25:295–330.
   PubMed Web of Science ®Google Scholar
• Manji HK, Potter WZ, Lenox RH. Signal transduction path- ways: molecular targets for lithium’s actions. Arch Gen Psy- chiatry 1995;52:531–43.
   PubMed Web of Science ®Google Scholar
• Striplin CD, Kalivas PW. Correlation between behavioral sensitization to cocaine and G protein ADP-ribosylation in the ventral tegmental area. Brain Res 1992;579:181–6.
   Google Scholar
• Fischer F. Zur Lehre vom epileptischen Irresein. Arch Psych- iatrie Nervenkr 1884;15:741–76.
   Google Scholar
• Christinger M. U¨ ber den Einfluß einer wirksamen Epilepsie- behandlung auf die Psyche der Epileptiker. Epilepsia 1914; 5:223–42.
   Google Scholar
• Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active- control trial. Neurology 1998;51:48–55.
   PubMed Web of Science ®Google Scholar
• Harden CL, Pulver MC, Nikolov B, Halper JP, Labar DR. Effect of vagus nerve stimulation on mood in adult epilepsy patients [Abstract]. Neurology 1999;52(suppl 2):A238.
   Google Scholar
• Robertson MM, Trimble MR, Townsend HRA. Phenomenol- ogy of depression in epilepsy. Epilepsia 1987;28:364–72.
   PubMed Web of Science ®Google Scholar
• Monroe RR, Wise SP III. Combined phenothiazine, chlordiaz- epoxide and primidone therapy for uncontrolled psychotic patients. Am J Psychiatry 1965;122:694–8.
   Google Scholar
• Hayes SG. Barbiturate anticonvulsants in refractory af- fective disorders. Ann Clin Psychiatry 1993;5:35–44.
   Google Scholar
• Schaffer LC, Schaffer CB, Caretto J. The use of primidone in the treatment of refractory bipolar disorder. Ann Clin Psychi- atry 1999;11:61–6.
   Google Scholar
• Kalinowsky LB, Putnam TJ. Attempts at treatment of schizophrenia and other nonepileptic psychoses with Dilan- tin. Arch Neurol Psychiatry 1943;49:414–20.
   Google Scholar
• Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phe- nytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000;157:463–5.
   PubMed Web of Science ®Google Scholar
• Johannessen CU. Mechanisms of action of valproate: a com- mentatory. Neurochem Int 2000;37:103–10.
   PubMed Web of Science ®Google Scholar
• Mu¨ ller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol 2000;20:195–203.
   Google Scholar
• Lambert PA, Carraz G, Borselli S, Carvel S. Action neuro- psychotrope d’un nouvel anti-e´pileptique: le de´pamide. Ann Med Psychol 1966;124:707–10.
   Google Scholar
• McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 1992;12(1, suppl):42–52S.
   Google Scholar
• Emrich HM, Von Zerssen D, Kissling W, Mo¨ller HJ, Win- dorfer A. Effect of sodium valproate on mania: the GABA- hypothesis of affective disorders. Arch Psychiatrie Nervenkr 1980;229:1–16.
   Google Scholar
• Brennan MJW, Sandyk R, Borsook D. Use of sodium val- proate in the management of affective disorders: basic and clinical aspects. In: Emrich HM, Okuma T, Mu¨ ller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Elsev- ier, 1984:56–65.
   Google Scholar
• Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991;48:62–8.
   Google Scholar
• McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI, Morris D. Correlates of antimanic response to valproate. Psychophar- macol Bull 1991;27:127–33.
   PubMed Web of Science ®Google Scholar
• Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149:108–11.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al. Efficacy of divalproex vs. lithium and pla- cebo in the treatment of mania. JAMA 1994;271:918–24.
   Google Scholar
• McElroy SL, Keck PE Jr, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142–6.
   PubMed Web of Science ®Google Scholar
• Vasudev K, Goswami U, Kohli K. Carbamazepine and val-proate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psycho- pharmacology 2000;150:15–23.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Davis J, Morris D, Swann A, Calabrese J, Lam- bert M, et al. Effect size of efficacy measures comparing di- valproex, lithium and placebo in acute mania. Depress Anx 1997;6:26–30.
   Google Scholar
• Sharma V, Yatham LN, Haslam DRS, Silverstone PH, Parikh SV, Matte R, et al. Continuation and prophylactic treatment of bipolar disorder. Can J Psychiatry 1997;42(suppl 2):92– 100S.
   Google Scholar
• Sachs GS, Thase ME. Bipolar disorder therapeutics: mainte- nance treatment. Biol Psychiatry 2000;48:573–81.
   PubMed Web of Science ®Google Scholar
• Moncrieff J. Lithium revisited: a re-examination of the placebo-controlled trials of lithium prophylaxis in manic- depressive disorder. Br J Psychiatry 1995;167:569–73.
   PubMed Web of Science ®Google Scholar
• Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999;100:406–17.
   PubMed Web of Science ®Google Scholar
• Emrich HM, Wolf R. Valproate treatment of mania. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:691–701.
   Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481–9.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tohen M, Tondo L. Maintenance treatment in bipolar disorder. Arch Gen Psychiatry 2000;57:490–2.
   PubMed Web of Science ®Google Scholar
• Solomon DA, Keitner GI, Ryan CE, Miller IW. Lithium plus valproate as maintenance polypharmacy for patients with bi- polar I disorder: a review. J Clin Psychopharmacol 1998; 18:38–49.
   PubMed Web of Science ®Google Scholar
• Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A, et al. A pilot study of lithium carbonate plus dival- proex sodium for the continuation and maintenance treat- ment of patients with bipolar I disorder. J Clin Psychiatry 1997;58:95–9.
   PubMed Web of Science ®Google Scholar
• Post RM, Weiss SRB, Chung D, Ketter TA. Mechanism of action of carbamazepine in seizure and affective disorders. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in mood dis- orders. New York: Dekker, 1999:43–92.
   Google Scholar
• Dunn RT, Frye MS, Kimbrell TA, Denicoff KD, Leverich GS, Post RM. The efficacy and use of anticonvulsants in mood disorders. Clin Neuropharmacol 1998;21:215–35.
   PubMed Web of Science ®Google Scholar
• Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35(suppl 3): S10–3.
   Google Scholar
• Ballenger JC, Post RM. Therapeutic effects of carbamazep- ine in affective illness: a preliminary report. Commun Psy- chopharmacol 1978;2:159–75.
   Google Scholar
• McElroy SL, Keck PE Jr. Pharmacologic agents for the treat- ment of acute bipolar mania. Biol Psychiatry 2000;48:539–57.
   PubMed Web of Science ®Google Scholar
• Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S. Carba- mazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987;48:89–93.
   PubMed Web of Science ®Google Scholar
• Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991; 48:915–21.
   PubMed Web of Science ®Google Scholar
• Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Ha- zama H, et al. Comparison of the antimanic efficacy of carba- mazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology 1979;66:211–7.
   Google Scholar
• Grossi E, Sacchetti E, Vita A, Conte G, Faravelli C, Hautman G, et al. Carbamazepine versus chlorpromazine in mania: a double-blind trial. In: Emrich HM, Okuma T, Mu¨ ller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984:177–87.
   Google Scholar
• Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Correlates of antimanic response to carbamazepine. Psychiatry Res 1987; 21:71–83.
   PubMed Web of Science ®Google Scholar
• Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993;27:138–45.
   PubMed Web of Science ®Google Scholar
• Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Ha- zama H, et al. A preliminary double-blind study on the effi- cacy of carbamazepine in prophylaxis of manic-depressive ill- ness. Psychopharmacology 1981;73:95–6.
   Google Scholar
• Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 pa- tients. J Clin Psychiatry 1986;47:490–4.
   PubMed Web of Science ®Google Scholar
• Watkins SE, Callender K, Thomas DR, Tidmarsh SF, Shaw DM. The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987;150:180–2.
   PubMed Web of Science ®Google Scholar
• Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lith- ium in the treatment and prophylaxis of mania. Br J Psychi- atry 1988;153:198–204.
   PubMed Web of Science ®Google Scholar
• Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85:114–8.
   PubMed Web of Science ®Google Scholar
• Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Lev- erich GS, Post RM. Comparative prophylactic efficacy of lith- ium, carbamazepine, and the combination in bipolar disor- der. J Clin Psychiatry 1997;58:470–8.
   Google Scholar
• Post RM, Leverich GS, Rosoff AS, Altshuler LL. Carbama- zepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990; 10:318–27.
   PubMed Web of Science ®Google Scholar
• Pazzaglia PJ, Post RM. Contingent tolerance and reresponse to carbamazepine: a case study in a patient with trigeminal neuralgia and bipolar disorder. J Neuropsychiatry Clin Neu- rosci 1992;4:76–81.
   Google Scholar
• Frankenburg FR, Tohen M, Cohen BM, Lipinski JF. Long- term response to carbamazepine: a retrospective study. J Clin Psychopharmacol 1988;8:130–2.
   PubMed Web of Science ®Google Scholar
• Xie X, Hagan RM. Cellular and molecular actions of lamo- trigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998;38:119–30.
   PubMed Web of Science ®Google Scholar
• Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607–14.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamo-trigine monotherapy in outpatients with bipolar I depres- sion. J Clin Psychiatry 1999;60:79–88.
   PubMed Web of Science ®Google Scholar
• Ichim L, Berk M, Brook S. Lamotrigine compared with lith- ium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 2000;12:5–10.
   PubMedGoogle Scholar
• Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharmacol 1999;9(suppl 4): S119–23.
   Google Scholar
• Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al. A double-blind, placebo-controlled, pro- phylaxis study of lamotrigine in rapid-cycling bipolar disor- der. J Clin Psychiatry 2000;61:841–50.
   PubMed Web of Science ®Google Scholar
• Kotler M, Matar MA. Lamotrigine in the treatment of resis- tant bipolar disorder. Clin Neuropharmacol 1998;21:65–7.
   Google Scholar
• Wong IC, Mawer GE, Sander JW. Factors influencing the in- cidence of lamotrigine-related skin rash. Ann Pharmacother 1999;33:1037–42.
   PubMedGoogle Scholar
• Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233–49.
   PubMed Web of Science ®Google Scholar
• McLean MJ, Gabapentin: chemistry, absorption, distribu- tion, and excretion. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven, 1995: 843–9.
   Google Scholar
• Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000;2:249–55.
   PubMed Web of Science ®Google Scholar
• Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar disorder [Letter]. Am J Psychiatry 1997;154:291–2.
   PubMedGoogle Scholar
• Schaffer CB, Schaffer LC. Open maintenance treatment of bipolar disorder spectrum patients who responded to gaba- pentin augmentation in the acute phase of treatment. J Af- fect Disord 1999;55:237–40.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Soutullo CA, Keck PE Jr, Kmetz GF. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997;9:99–103.
   PubMedGoogle Scholar
• Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997;42:851–3.
   Google Scholar
• Knoll J, Stegman K, Suppes T. Clinical experience using ga- bapentin adjunctively in patients with a history of mania or hypomania. J Affect Disord 1998;49:229–33.
   PubMed Web of Science ®Google Scholar
• Erfurth A, Kammerer C, Grunze H, Normann C, Walden J. An open label study of gabapentin in the treatment of acute mania. J Psychiatr Res 1998;32:261–4.
   Google Scholar
• Perugi G, Toni C, Ruffolo G, Sartini S, Simonini E, Akis- kal H. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmaco- psychiatry 1999;32:136–41.
   Google Scholar
• Young LT, Robb JC, Hasey GM, MacQueen GM, Patelis Siotis I, Marriott M, et al. Gabapentin as an adjunctive treatment in bipolar disorder. J Affect Disord 1999;55:73–7.
   PubMed Web of Science ®Google Scholar
• Sokolski KN, Green C, Maris DE, DeMet EM. Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. Ann Clin Psychiatry 1999; 11:217–22.
   PubMedGoogle Scholar
• Altshuler LL, Keck PE Jr, McElroy SL, Suppes T, Brown ES, Denicoff K, et al. Gabapentin in the acute treatment of re- fractory bipolar disorder. Bipolar Disord 1999;1:61–5.
   PubMedGoogle Scholar
• Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998;50:245–51.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, McElroy SL, Werkner JE. Topira- mate in severe treatment-refractory mania. Presented at the 151st Annual Meeting of the American Psychiatric Associa- tion, Toronto, May 1998.
   Google Scholar
• Kusumakar V, Lakshmi N, Yatham MB, O’Donovan CA, Kutcher SP. Topiramate in rapid cycling bipolar women. Pre- sented at the 152nd Annual Meeting of the American Psychi- atric Association, Washington, DC, May 1999.
   Google Scholar
• Roy Chengappa KN, Rathore D, Levine J, Atzert R, Solai L, Parepally H, et al. Topiramate as add-on treatment for pa- tients with bipolar mania. Bipolar Disord 1999;1:42–53.
   Google Scholar
• McElroy SL, Suppes T, Keck PE Jr, Frye MA, Denicoff KD, Altshuler LL, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47:1025–33.
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Chapman AG. Basic mechanisms of Gabitril (tiagabine) and future potential developments. Epilepsia 1999;40(suppl 9): S2–6.
   Google Scholar
• Kaufman KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 1998;10:181–4.
   PubMedGoogle Scholar
• Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder [Letter]. Am J Psychiatry 1999; 156:2014–5.
   PubMed Web of Science ®Google Scholar
• Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999;60:759–62.
   PubMed Web of Science ®Google Scholar